Form 0920-23AA Att. 4b Key Informant Interview Protocol - Evaluator

Attachment 4b. Instrument and Protocol: Key Informant Interview – Evaluator
Form Approve
OMB No: xxxx-xxxx
Exp. Date: xx-xx-xxxx
Public Reporting burden of this collection of information is estimated at 30 minutes, including the time for reviewing
instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing
the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a
collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden
estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR
Reports Clearance Officer, 1600 Clifton Road NW, MS D-74, Atlanta, GA 30333; Attn: PRA (xxxx-xxxx).

INTRODUCTION AND WELCOME
Thank you for meeting with us today. My name is <> and on the call is my colleague <>, and we are with Centers for Disease Control and Prevention (CDC). We are conducting qualitative
interviews with State Domestic Violence Coalition Project Leads who are overseeing DELTA AHEAD initiatives in
their state. This will help us understand how DELTA AHEAD program and policy efforts (PPEs) are being
implemented to prevent Intimate Partner Violence (IPV).
We plan for this interview to take no longer than 30 minutes. We are interested in hearing your honest and
candid responses. Your participation is voluntary, and you may choose not to answer any questions without
penalty. You may end the interview at any time. Your participation or recusal will not affect your funding or
relationship with the funders.
Information collected from this interview will inform CDC’s evaluation of the DELTA AHEAD initiative and help to
inform future NOFOs. We will conduct analysis to aggregate findings across participants. The aggregated
findings will be shared with DELTA AHEAD recipients and other key partners in IPV violence prevention work.
Data contained in the analysis will not link your name, role, or Coalition to any specific responses in any reports
developed from this project.
<> will be taking notes during the interview so that we accurately capture your views and
experiences. All information we collect from you will be kept secured and the only people who will have access
to identifiable information are the CDC team involved in the project. We would also like to audio-record today’s
interview. The audio-recording will be used to supplement our notes and will not be shared outside our project
team. It will be destroyed at the completion of the project.
Do I have your permission to record this interview? [Facilitator should note that every participant has
responded]
[IF NO  Thank participant and confirm that the interview will not be recorded.]
[IF YES  Thank participant and confirm their verbal consent.]
Do you have any questions for me about our meeting before we begin? [Pause for participant response.]
Please feel free to ask questions at any time during the discussion.

Okay. We are ready to begin, so I will turn on the recorder. <>
Interviewer Notes:
1. Tailor the discussion guide based on the interviewee and their role.

SECTION 1: EVALUATOR ROLE

We’d like to start by asking about your role as an evaluator of the DELTA AHEAD program in your state.
1. Please describe your relationship to the coalition regarding evaluation.
a. Are you an employee of the coalition or a contractor outside of the coalition?
b. How do you interact and coordinate with the DELTA AHEAD coalition team at the state levels
and community levels (CCRs)?
2. Please describe the process for how the coalition and the Coordinated Community Response Teams
(CCRTs) initiate and/or coordinate with you on evaluation efforts for the project.
SECTION 2: STATE- AND COMMUNITY-LEVEL PPE EVALUATION

3. What factors have facilitated or impeded your evaluation efforts at the state level?
4. What factors have facilitated or impeded your evaluation efforts with the community level teams?
5. What changes, if any, have you observed in local level partners’ attitudes toward evaluating IPV
primary prevention work?
SECTION 3: USE OF DATA

6. How do you use data and evaluation work to inform DELTA AHEAD and PPE-specific activities?
a. How do you use data on social determinants of health to inform planning and implementation
of DELTA activities?
7. How have you used surveillance data to establish baseline indicator data and to monitor changes at
the state- and community-levels over time?
8. How do you plan to share evaluation findings with partners?
SECTION 4: CAPACITY BUILDING

9. Since March 2023, what changes have you noticed in your coalition’s capacity to evaluate PPEs
implemented at the state level? (Category B)
a. What changes have you seen in the Coordinated Community Response Teams’ capacity to
evaluate PPEs at the local or community level?

10. What are the biggest challenges you experience as an evaluator of this program?
b. How, if at all, are these challenges different at the state and community levels?
SECTION 5: HEALTH EQUITY

11. How, if at all, have you incorporated health equity into the evaluation of DELTA AHEAD?
a. What challenges have you faced with incorporating health equity?
b. How have you, or do you plan to, overcome these challenges?
c. If you have not incorporated health equity into the evaluation of DELTA AHEAD, can you please
explain why?
CLOSING AND THANK YOU
12. What are the most important lessons you have learned about evaluating IPV Primary Prevention
strategies that would you share with unfunded states?
Before we conclude our discussion, is there anything that we have not discussed that you think would be
important for us to know?
Do you have any questions for me? [Address any questions]
Thank you again for taking the time to speak with me. We sincerely appreciate and value your input

a.